Clement Agyemang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Clement Agyemang has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Andrew Futreal
Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA
14 shared publications - Anthony Paul Conley
Department of Sarcoma Medical Oncology, Division of Cancer Medicine, University of Texas, MD Anderson Cancer Center, Houston, TX, United States
14 shared publications - Asmaa Ahmed
The University of Texas MD Anderson Cancer Center 2 Sarcoma Medical Oncology Houston, Texas
14 shared publications - Bissan Al-Lazikani
Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA
14 shared publications - Carl Ho
The University of Texas MD Anderson Cancer Center 1 Department of Genomic Medicine Houston, Texas
14 shared publications - Clifford Stephan
Texas A&M Health Center for Translational Cancer Research, Houston, TX 77030, USA
14 shared publications
Latest Publications
- Open Access
- 31 July 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S1 from Drug Screening of Sarcoma Cells: Finding Shared Sensitivities
Figure S1. Unsupervised hierarchical clustering of drug AUC values after filtering for min = 0.2 (blue) and max = 0.7 (red).
- 31 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S1 from Drug Screening of Sarcoma Cells: Finding Shared Sensitivities
Figure S1. Unsupervised hierarchical clustering of drug AUC values after filtering for min = 0.2 (blue) and max = 0.7 (red).
- Open Access
- 31 July 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S2 from Drug Screening of Sarcoma Cells: Finding Shared Sensitivities
Figure S2. Heatmap of the CDK2, CDK7, and CDK9 expression in sarcoma cells from the Cancer Cell Line Encyclopedia (CCLE) database.
- 31 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S2 from Drug Screening of Sarcoma Cells: Finding Shared Sensitivities
Figure S2. Heatmap of the CDK2, CDK7, and CDK9 expression in sarcoma cells from the Cancer Cell Line Encyclopedia (CCLE) database.
- Open Access
- 31 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Drug Screening of Sarcoma Cells: Finding Shared Sensitivities
Table S2. Top 30 ranking sensitive compound for each cell line
- 31 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Drug Screening of Sarcoma Cells: Finding Shared Sensitivities
Table S2. Top 30 ranking sensitive compound for each cell line
- Open Access
- 31 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Drug Screening of Sarcoma Cells: Finding Shared Sensitivities
Supplementary Table S1 from Drug Screening of Sarcoma Cells: Finding Shared Sensitivities
- 31 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Drug Screening of Sarcoma Cells: Finding Shared Sensitivities
Supplementary Table S1 from Drug Screening of Sarcoma Cells: Finding Shared Sensitivities
- Open Access
- 31 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Drug Screening of Sarcoma Cells: Finding Shared Sensitivities
Table S3. Extraction of intersections from the upset plot (Figure 3). Cell lines are colored according to histology (color scheme from Figure 3).
- 31 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Drug Screening of Sarcoma Cells: Finding Shared Sensitivities
Table S3. Extraction of intersections from the upset plot (Figure 3). Cell lines are colored according to histology (color scheme from Figure 3).
- Open Access
- 31 July 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S3 from Drug Screening of Sarcoma Cells: Finding Shared Sensitivities
Figure S3. Loading control for the Western blots in Figure 3 of GAPDH for each of the myxoid liposarcoma cell lines: DDL-221, MLS-401-91, and MLS-1765-92.
- 31 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S3 from Drug Screening of Sarcoma Cells: Finding Shared Sensitivities
Figure S3. Loading control for the Western blots in Figure 3 of GAPDH for each of the myxoid liposarcoma cell lines: DDL-221, MLS-401-91, and MLS-1765-92.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Drug Screening of Sarcoma Cells: Finding Shared Sensitivities
Many of the >130 World Health Organization–defined sarcoma subtypes are chemoresistant. To identify drug candidates with potential for repurposing in sarcomas with unmet needs, we screened structurally diverse small molecules across 20 sarcoma cell lines of various histologies. The screen included 1,387 compounds from the Custom Clinical Collection, NCI-Approved Oncology Set IV, and Selleck Bioactive Collection. The most effective agents were microtubule inhibitors, aurora kinase inhibitors, and heat shock protein inhibitors. Differential drug sensitivity was observed by sarcoma subtype. Ewing sarcoma, for example, was sensitive to aurora kinases and to TORIN-2 (an mTOR inhibitor). In contrast, myxoid liposarcoma and synovial sarcomas exhibited marked sensitivity to SNS-032, a CDK2/7/9 inhibitor identified by our screen. Interestingly, SNS-032 abrogates the downstream YAP pathway, a known driver pathway in the growth of these histotypes. Therefore, similar drug responses across histologies may indicate shared driver pathways and vulnerabilities.Significance:Sarcoma cells are resistant to most compounds that are currently approved for treating various diseases. Ewing sarcoma cells have distinct sensitivities to aurora kinases that can be explored, whereas myxoid liposarcoma and synovial sarcoma cells share similar drug sensitivity fingerprints that could be exploited in future basket trials.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Drug Screening of Sarcoma Cells: Finding Shared Sensitivities
Many of the >130 World Health Organization–defined sarcoma subtypes are chemoresistant. To identify drug candidates with potential for repurposing in sarcomas with unmet needs, we screened structurally diverse small molecules across 20 sarcoma cell lines of various histologies. The screen included 1,387 compounds from the Custom Clinical Collection, NCI-Approved Oncology Set IV, and Selleck Bioactive Collection. The most effective agents were microtubule inhibitors, aurora kinase inhibitors, and heat shock protein inhibitors. Differential drug sensitivity was observed by sarcoma subtype. Ewing sarcoma, for example, was sensitive to aurora kinases and to TORIN-2 (an mTOR inhibitor). In contrast, myxoid liposarcoma and synovial sarcomas exhibited marked sensitivity to SNS-032, a CDK2/7/9 inhibitor identified by our screen. Interestingly, SNS-032 abrogates the downstream YAP pathway, a known driver pathway in the growth of these histotypes. Therefore, similar drug responses across histologies may indicate shared driver pathways and vulnerabilities.Significance:Sarcoma cells are resistant to most compounds that are currently approved for treating various diseases. Ewing sarcoma cells have distinct sensitivities to aurora kinases that can be explored, whereas myxoid liposarcoma and synovial sarcoma cells share similar drug sensitivity fingerprints that could be exploited in future basket trials.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Drug Screening of Sarcoma Cells: Finding Shared Sensitivities
Table S2. Top 30 ranking sensitive compound for each cell line
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Drug Screening of Sarcoma Cells: Finding Shared Sensitivities
Table S2. Top 30 ranking sensitive compound for each cell line
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Drug Screening of Sarcoma Cells: Finding Shared Sensitivities
Table S3. Extraction of intersections from the upset plot (Figure 3). Cell lines are colored according to histology (color scheme from Figure 3).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Drug Screening of Sarcoma Cells: Finding Shared Sensitivities
Table S3. Extraction of intersections from the upset plot (Figure 3). Cell lines are colored according to histology (color scheme from Figure 3).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Drug Screening of Sarcoma Cells: Finding Shared Sensitivities
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Drug Screening of Sarcoma Cells: Finding Shared Sensitivities